Crohn-betegség: vizsgálatok itt: Csehország
25 of 25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleCrohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
- Where
- Brno, Brno-Zidenice, Hradec Králové, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 302 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-521590-13-00 - 3. fázisFut, nem toborozA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Brno-Stred, Brno-Zidenice, Hradec Králové, Prague, Slaný
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno-Sever, České Budějovice, Hradec Králové, Novy Hradec Kralove
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 3. fázisTaking peopleA clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
- Where
- Brno-Stred, Brno-Zidenice, Hradec Králové, Prague, Slaný
- Életkor
- 18 év and over
- People
- 567 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 - 3. fázisTaking peopleExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Where
- Brno-Zidenice, Hradec Králové
- Életkor
- 18 év and over
- People
- 1380 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Brno-Sever, Brno-Zidenice, Prague 4, Prague 5
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 2/3. fázisTaking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Brno-Zidenice, Kladno, Olomouc, Pardubice, Prague, Prague 4
- Életkor
- 18 év and over
- People
- 1092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - 3. fázisTaking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Hradec Kralova, Hradec Králové, Ostrava - Poruba, Prague
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Hradec Králové, Kladno, Ostrava, Prague
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - 2. fázisTaking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Brno-Sever, Brno-Zidenice, České Budějovice, Hradec Králové, Olomouc, Ostrava, Pardubice, Prague, Prague 5, Slezska Ostrava, Ústí nad Labem
- Életkor
- 18 év to 75 év
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Where
- Brno-Zidenice, České Budějovice, Hradec Králové, Olomouc, Slaný
- Életkor
- 18 év to 75 év
- People
- 99 worldwide
- Run by
- Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Hradec Králové, Ostrava, Prague, Usti Nad Labem
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Brno, Hradec Králové, Prague
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Hradec Králové, Prague
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisBefejeződöttA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Novy Hradec Kralove, Prague 2, Prague 5
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - No phaseTaking peopleImpact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's Disease
- Where
- Prague
- Életkor
- 10 év to 18 év
- People
- 124
- Run by
- University Hospital, Motol
See details and how to joinNCT07884045 - 2. fázisTaking peopleA clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
- Where
- Brno, Brno-Sever, Brno-Zidenice, Prague
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Brno-Sever, Hradec Králové, Prague
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - 3. fázisTaking peopleA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Where
- České Budějovice, Hradec Králové, Prague
- Életkor
- 18 év to 65 év
- People
- 396 worldwide
- Run by
- Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00 - 2. fázisTaking peopleA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Where
- Brno, Brno-Sever, Brno-Zidenice, České Budějovice, Hradec Králové, Ostrava, Pardubice, Prague, Prague 5, Slezska Ostrava, Usti Nad Labem
- Életkor
- 18 év to 75 év
- People
- 192 worldwide
- Run by
- Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00 - 3. fázisVisszavonvaA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Prague
- Életkor
- 2 év to 17 év
- People
- 240 worldwide
- Run by
- Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00 - 3. fázisNot yet taking people in CsehországA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Where
- Ostrava, Prague
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00 - 2. fázisTaking peopleEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Where
- Brno-Sever, Brno-Zidenice, Hradec Králové, Olomouc, Prague, Slaný
- Életkor
- 18 év to 75 év
- People
- 212 worldwide
- Run by
- Abivax S.A.
See details and how to joinNCT06456593 · EU 2023-508234-34-00 - 4. fázisNot yet taking people in CsehországVECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
- Where
- Brno
- Életkor
- 18 év to 80 év
- People
- 304 worldwide
- Run by
- Alimentiv Inc.
See details and how to joinNCT06257706 · EU 2023-509096-16-00